Alternating vector immunizations encoding pre‐erythrocytic malaria antigens enhance memory responses in a malaria endemic area
- 27 July 2006
- journal article
- clinical trial
- Published by Wiley in European Journal of Immunology
- Vol. 36 (8) , 2264-2272
- https://doi.org/10.1002/eji.200636187
Abstract
A heterologous prime‐boost strategy has been developed to potently induce T cell responses to pre‐erythrocytic malaria antigens. Efficacy in the field is likely to depend on both peak immunogenicity and the durability of responses. To improve both immunogenicity and durability of responses, 54 adult males from a malaria endemic area were immunized with different vaccination regimens, systematically varying antigenic insert and the number and sequence of component vaccinations. The component vaccinations were recombinant attenuated viruses, either fowlpox (FP) 9 or modified vaccinia virus Ankara (MVA). These were recombinant for either of two pre‐erythrocytic malaria antigens (multiple epitope‐thrombospondin‐related adhesion protein, ME‐TRAP, or circumsporozoite antigen (CS). ELISPOT assays were used to measure the effector and resting memory T cell responses. Sequence, antigen insert and number of vaccinations influenced immunogenicity, but the novel alternating vector immunizations generated the largest resting memory T cell populations. Effector responses were maintained at 84% of the peak response after 270 days. This durability of response is unprecedented. Classical prime‐boost vaccination responses were at 5% of the peak after 270 days. Vaccines administered by heterologous prime‐boost regimes are being developed for diverse pathogens and cancer. These data suggest these vaccines should also be administered by alternating vector regimens in clinical development.Keywords
This publication has 22 references indexed in Scilit:
- Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-LengthPlasmodium falciparumCircumsporozoite ProteinInfection and Immunity, 2006
- A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CSVaccine, 2006
- Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motifVaccine, 2004
- CD8+ T cell contraction is controlled by early inflammationNature Immunology, 2004
- Phase 1 Evaluation of 3 Highly Immunogenic Prime‐Boost Regimens, Including a 12‐Month Reboosting Vaccination, for Malaria Vaccination in Gambian MenThe Journal of Infectious Diseases, 2004
- Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humansNature Medicine, 2003
- Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria VaccineThe Journal of Infectious Diseases, 1999
- A protein particle vaccine containing multiple malaria epitopesNature Biotechnology, 1997
- ‘Original antigenic sin’, T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasionParasite Immunology, 1993
- Common West African HLA antigens are associated with protection from severe malariaNature, 1991